Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part D Step Therapy Coverage | …
    Ask Trek AI about this page
    CurrentIndependent HealthPolicy N/A

    Step therapy requirements for select Part D drugs

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy (prior authorization alternative therapy sequencing) requirements for specific drugs on Independent Health's Medicare Advantage Part D formularies; affects prescribers and pharmacy benefit administrators for Medicare Advantage members.

    Policy Summary
    PayerIndependent Health
    PolicyStep therapy requirements for select Part D drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionRequire prior trial of the specified preferred agent (e.g., ARB before aliskiren 300 mg) before coverage of the listed non-preferred alternative.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12distinct product entries listed
    Medicare Part Dformulary type governed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Requires prior trialmost entries impose prior trial

    Step Therapy / Initial Coverage Criteria

    Initial step therapy requirements

    Covered only after failure or trial of specified first-line agent(s):

    Aliskiren 300 mg: Requires prior trial of an angiotensin-II receptor blocker (ARB)

    chunk 2

    Aripiprazole formulations: Aripiprazole ODT requires prior use of aripiprazole oral solution; aripiprazole oral films require prior use of aripiprazole ODT

    chunk 4

    EUCRISA ointment: Requires prior use of either a topical corticosteroid OR a topical calcineurin inhibitor

    chunk 6

    Febuxostat 40 mg and 80 mg: Requires prior use of allopurinol

    chunk 8

    Sympazan films: Requires prior use of clobazam oral suspension

    chunk 10

    Trelstar MixJect formulations: Requires prior use of Lupron Depot

    chunk 12

    Versacloz suspension: Requires prior use of clozapine ODT

    chunk 13

    Doxercalciferol 2.5 mcg: Requires prior use of calcitriol

    chunk 14

    Aliskiren

    Aliskiren 300 mg: Requires prior trial of an angiotensin-II receptor blocker (ARB)

    chunk 2

    Aripiprazole

    Aripiprazole formulations: Aripiprazole ODT requires prior use of aripiprazole oral solution; aripiprazole oral films require prior use of aripiprazole ODT

    chunk 4

    EUCRISA

    EUCRISA ointment: Requires prior use of either a topical corticosteroid OR a topical calcineurin inhibitor

    chunk 6

    Febuxostat

    Febuxostat: Requires prior use of allopurinol

    chunk 8

    Sympazan

    Sympazan films: Requires prior use of clobazam oral suspension

    chunk 10

    Trelstar

    Trelstar MixJect formulations: Requires prior use of Lupron Depot

    chunk 12

    Versacloz

    Versacloz suspension: Requires prior use of clozapine orally-disintegrating tablet (ODT)

    chunk 13

    Doxercalciferol

    Doxercalciferol 2.5 mcg: Requires prior use of calcitriol

    chunk 14

    Provider Notices and Actionable Product Sequencing

    Note

    Member contact and notices

    This list is current as of 2026-06-01 and pertains to Independent Health Medicare Advantage Part D formularies. In some cases, we require that a member try certain drugs first (step therapy) before we will cover another drug for the same condition. If you have questions, contact Medicare Member Services at 1-800-665-1502 (TTY 711). October 1 - March 31: daily 8 a.m. - 8 p.m.; April 1 - September 30: Monday - Friday 8 a.m. - 8 p.m. The formulary may change at any time; members will receive notice when necessary.

    Step Therapy

    EUCRISA step requirement

    EUCRISA (crisaborole) ointment requires that the member first try a topical corticosteroid or a topical calcineurin inhibitor prior to coverage under the Part D formulary.

    • Applies to EUCRISA ointment (topical crisaborole).
    • Step therapy: trial of a topical corticosteroid OR a topical calcineurin inhibitor required before coverage.
    Step Therapy

    Required First-Line Agents and Sequencing Table

    DrugStep therapy requirementCoverage status
    Aliskiren fumarate tablet 300 mg oral
    Requires prior trial of an angiotensin‑II receptor blocker (ARB)
    Covered with criteria
    DrugStep therapy requirementCoverage status
    Aripiprazole orally‑disintegrating tablet (ODT)
    Requires prior use of aripiprazole oral solution before ODT; aripiprazole oral films require prior use of ODT
    Covered with criteria
    DrugStep therapy requirementCoverage status
    EUCRISA ointment
    Requires prior use of either a topical corticosteroid OR a topical calcineurin inhibitor
    Covered with criteria
    DrugStep therapy requirementCoverage status
    Febuxostat tablet 40 mg and 80 mg
    Requires prior use of allopurinol
    Covered with criteria
    DrugStep therapy requirementCoverage status
    SYMPAZAN film (all strengths)
    Requires prior use of clobazam oral suspension
    Covered with criteria
    DrugStep therapy requirementCoverage status
    TRELSTAR MixJect formulations (reconstituted)
    Requires prior use of Lupron Depot
    Covered with criteria
    DrugStep therapy requirementCoverage status
    VERSACLOZ suspension 50 mg/mL oral
    Requires prior use of clozapine orally‑disintegrating tablet (ODT)
    Covered with criteria
    DrugStep therapy requirementCoverage status
    Doxercalciferol capsule 2.5 mcg oral
    Requires prior use of calcitriol
    Covered with criteria
    Policy Summary
    PayerIndependent Health
    PolicyStep therapy requirements for select Part D drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionRequire prior trial of the specified preferred agent (e.g., ARB before aliskiren 300 mg) before coverage of the listed non-preferred alternative.
    SourceLink
    On This Page
    Step Therapy / Initial Coverage CriteriaProvider Notices and Actionable Product SequencingRequired First-Line Agents and Sequencing Table

    Febuxostat step requirement

    Febuxostat (both 40 mg and 80 mg formulations) requires prior use of allopurinol before coverage will be approved under the Part D formulary.

    • Applies to febuxostat tablets (including 80 mg).
    • Step therapy: trial of allopurinol required prior to approval.
    Step Therapy

    SYMPAZAN step requirement

    SYMPAZAN oral films require that the member first try clobazam oral suspension prior to coverage under the Part D formulary.

    • Applies to SYMPAZAN films (e.g., 5 mg).
    • Step therapy: trial of clobazam oral suspension required before coverage.
    Step Therapy

    Doxercalciferol step requirement

    Doxercalciferol 2.5 mcg capsule requires prior use of calcitriol before coverage is approved under the Part D formulary.

    • Applies to doxercalciferol capsule 2.5 mcg.
    • Step therapy: trial of calcitriol required prior to coverage.